Mesenchymal stem cells expressing therapeutic genes induce autochthonous prostate tumour regression

European Journal of Cancer

Volumn 50, Issue 14, 2014, Pages 2478-2488

  Abrate, Alberto ^a   Buono, Roberta ^a   Canu, Tamara ^a   Esposito, Antonio ^a   Maschio, Alessandro Del ^a   Lucianó, Roberta ^a   Bettiga, Arianna ^a   Colciago, Giorgia ^a   Guazzoni, Giorgio ^a   Benigni, Fabio ^a   Hedlund, Petter ^a,b   Altaner, Cestmir ^c   Montorsi, Francesco ^a   Cavarretta, Ilaria T R ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b LINKÖPING UNIVERSITY   (Sweden)

^c CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

Magnetic resonance imaging; Mesenchymal stem cells; Prodrug activating enzymes; Prostate cancer; TRAMP mice

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; TACROLIMUS; URACIL PHOSPHORIBOSYLTRANSFERASE; GLYCOSYLTRANSFERASE; PRODRUG;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER REGRESSION; CONTROLLED STUDY; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; ADENOCARCINOMA; ANIMAL; BIOSYNTHESIS; BLOOD; C57BL MOUSE; CELL MOTION; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENE THERAPY; GENETICS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PHYSIOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RANDOMIZATION; TRANSGENIC MOUSE;

ADENOCARCINOMA; ANIMALS; CELL MOVEMENT; CYTOSINE DEAMINASE; DISEASE MODELS, ANIMAL; FLUCYTOSINE; GENETIC THERAPY; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PENTOSYLTRANSFERASES; PRODRUGS; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85027925705     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.06.014     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2013;63:11-30.
2. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2013;65:467-79.
3. Lassi K, Dawson NA. Emerging therapies in castrate-resistant prostate cancer. Curr Opin Oncol 2009;21:260-5.
4. Aboody KS, Najbauer J, Danks MK. Stem and progenitor cellmediated tumour selective gene therapy. Gene Ther 2008;15:739-52.
5. Shah K. Encapsulated stem cells for cancer therapy. Biomatter 2013;3 [in press].
6. Shah K. Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev 2012;64:739-48.
7. Wang H, Cao F, De A, et al. Trafficking mesenchymal stem cell engraftment and differentiation in tumour-bearing mice by bioluminescence imaging. Stem Cells 2009;27:1548-58.
8. Kidd S, Spaeth E, Dembinski JL, et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 2009;27:2614-23.
9. Dittmar T, Entschladen F. Migratory properties of mesenchymal stem cells. Adv Biochem Eng Biotechnol 2013;129:117-36.
10. Kucerova L, Altanerova V, Matuskova M, Tyciakova S, Altaner C. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res 2007;67:6304-13.
11. Kucerova L, Matuskova M, Pastorakova A, et al. Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. J Gene Med 2008;10:1071-82.
12. Altanerova V, Cihova M, Babic M, et al. Human adipose tissuederived mesenchymal stem cells expressing yeast cytosine deaminase:: uracil phosphoribosyltransferase inhibit intracerebral rat glioblastoma. Int J Cancer 2012;130:2455-63.
13. Cavarretta IT, Altanerova V, Matuskova M, Kucerova L, Culig Z, Altaner C. Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumour growth. Mol Ther 2010;18:223-31.
14. Erbs P, Regulier E, Kintz J, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000;60:3813-22.
15. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92:3439-43.
16. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM. Androgen independent prostate cancer progression in the TRAMP model. Cancer Res 1997;57:4687-91.
17. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997;57:3325-30.
18. Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED. The TRAMP mouse as a model for prostate cancer. In: Current Protocols in Immunology. In John Wiley & Sons Inc.: Hoboken, NJ; 2001. 20: pp. 5.1-5.23.
19. Suttie A, Nyska A, Haseman JK, Moser GJ, Hackett TR, Goldsworthy TL. A grading scheme for the assessment of proliferative lesions of the mouse prostate in the TRAMP model. Toxicol Pathol 2003;31:31-8.
20. Degl'Innocenti E, Grioni M, Boni A, Camporeale A, Bertilaccio MTS, Freschi M. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur J Immunol 2005;35: 66-75.
21. Pienta KJ, Abate-Shen C, Agus DB, et al. The current state of preclinical prostate cancer animal models. Prostate 2008;68: 629-39.
22. Khatri A, Zhang B, Doherty E, et al. Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice. J Gene Med 2006;8:1086-96.
23. Griffin MD, Ritter T, Mahon BP. Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther 2010;21:1641-55.
24. Niemeyer P, Vohrer J, Schmal H, et al. Survival of human mesenchymal stromal cells from bone marrow and adipose tissue after xenogenic transplantation in immunocompetent mice. Cytotherapy 2008;8:784-95.
25. Sbano P, Cuccia A, Mazzanti B, et al. Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. Arch Dermatol Res 2008; 300:115-24.
26. Ra JC, Shin IS, Kim SH, et al. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev 2011;20:1297-308.
27. Altaner C, Altanerova V, Cihova M, et al. Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario. Int J Cancer 2014;134:1458-65.
28. Gholamrezanezhad A, Mirpour S, Bagheri M, et al. In vivo tracking of 111In-oxide labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis. Nucl Med Bio 2011;38:961-7.
29. Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, et al. Safety of cell therapy with mesenchymal stromal cells (safecell): A systematic review and meta-analysis of clinical trials. PLoS ONE 2012;7 [in press].
30. Dachs GU, Tupper J, Tozer GM. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 2005;16:349-59.
31. Deak E, Ruester B, Keller L, Eckert K, Fichtner I, Seifried E, et al. Suspension medium influences interaction of mesenchymal stromal cells with endothelium and pulmonary toxicity after transplantation in mice. Cytotherapy 2010;12:260-4.
32. Fischer UM, Harting MT, Jimenez F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: The pulmonary first-pass effect. Stem Cells Dev 2009;18:683-92.
33. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001;169:12-20.
34. Daldrup-Link HE, Rudelius M, Metz S, et al. Cell tracking with gadophrin-2: A bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy. Eur J Nucl Med Mol Imaging 2004;31:1312-21.
35. Kang WJ, Kang HJ, Kim HS, Chung JK, Lee MC, Lee DS. Tissue distribution of 18F-FDG-labeled peripheral hematopoietic stem cells after intracoronary administration in patients with myocardial infarction. J Nucl Med 2006;47:1295-301.
36. Rochefort GY, Vaudin P, Bonnet N, et al. Influence of hypoxia on the domiciliation of mesenchymal stem cells after infusion into rats: possibilities of targeting pulmonary artery remodeling via cells therapies? Respir Res 2005;6:125-38.
37. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the antiinflammatory protein TSG-6. Cell Stem Cell 2009;5:54-63.
38. Schrepfer S, Deuse T, Reichenspurner H, Fischbein MP, Robbins RC, Pelletier MP. Stem cell transplantation: The lung barrier. Transplant Proc 2007;39:573-6.
39. Nystedt J, Anderson H, Tikkanen J, et al. Cell surface structures influence lung clearance rate of systemically infused mesenchymal stromal cells. Stem Cells 2013;31:317-26.
40. Kean TJ, Lin P, Caplan AI, Dennis JE. MSCs: delivery routes and engraftment, cell-targeting stratifies, and immune modulation. Stem Cells Int 2013 [in press].
41. Altaner C, Altanerova V. Stem cell based glioblastoma gene therapy. Neoplasma 2012;59:756-60.